Updated:
Alloy Ventures
Alloy Ventures is an early-stage venture capital firm with over $1 billion under management. It invests in Information Technology, Life Sciences, and Cleantech...
Alloy Ventures
Alloy Ventures is an early-stage venture capital firm with over $1 billion under management. It invests in Information Technology, Life Sciences, and Cleantech companies. The firm has made 328 investments, including a Series C - II investment in 3Spine on February 21, 2025.
General information
Firm type
Venture Capital
Year founded
1996
Location
Region
North America
Country
United States
City
Palo Alto
Corporate office
Palo Alto, CA, United States
Principals
Craig Taylor
General Partner
John Shoch
General Partner
Ammar Hanafi
General Partner
Sector focus
Frequently asked questions
Who runs investment decisions at Alloy Ventures?
General partners Craig Taylor, John Shoch, and Ammar Hanafi have historically led investment decisions. Taylor co-founded the firm in 1996 after operating roles at IBM and Telebit; Shoch was previously a partner at Asset Management Company. The partnership operated with a flat, consensus-driven structure rather than a single managing partner model.
Does Alloy participate in fund commitments or only direct deals?
Alloy operated as a direct-investment venture firm, not a fund-of-funds. The partnership deployed capital from its own closed-end funds directly into portfolio companies, occasionally co-investing alongside other Bay Area seed and Series A firms.
Which sectors does Alloy Ventures explicitly avoid?
Alloy did not explicitly publish a negative sector list, but its historical portfolio concentrated on enterprise software, cybersecurity, data infrastructure, semiconductors, and life sciences. The firm did not pursue consumer internet, media, or crypto-native investments as core thesis areas.
What are Alloy Ventures' most notable exits?
Two frequently cited outcomes are Applied Semantics, which Google acquired in 2003 for its AdSense technology, and Adamas Pharmaceuticals, which went public and later commercialized a Parkinson's disease therapy. These exits represent the firm's dual IT and life sciences focus.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: